Skip to main content

Table 1 Outline of planned treatment interventions by visit

From: Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial

 

Rituximab group

Cyclophosphamide group

Day 0

IV active rituximab 1000 mg

IV 600 mg mg/m2 body surface area

Day 14

IV active rituximab 1000 mg

Placebo

Week 4

Placebo

IV 600 mg mg/m2 body surface area

Week 8

Placebo

IV 600 mg mg/m2 body surface area

Week 12

Placebo

IV 600 mg mg/m2 body surface area

Week 16

Placebo

IV 600 mg mg/m2 body surface area

Week 20

Placebo

IV 600 mg mg/m2 body surface area

  1. IV intravenously administered
Back to article page

Trials

ISSN: 1745-6215